Company intelligence / Profile preview
Chaser Therapeutics
Hangzhou, Zhejiang Sheng, Chinachasertherapeutics.com ↗
- Ownership
- Private
- Development stage
- Preclinical
01
Overview
Chaser Therapeutics is a private Chinese biotech company founded in 2018, focused on developing small molecule drugs primarily targeting neoplasms such as refractory acute myeloid leukemia and triple negative breast cancer. Its lead asset PBSS-1113 targets the deubiquitinases USP25 and USP28 and has reached Phase 1 clinical trials. Another candidate, CT-300, is at preclinical stage for triple negative breast cancer. The company’s therapeutic focus also includes hemic/lymphatic diseases and skin/musculoskeletal diseases. No public information about clinical results or published data was found as of January 2025.
- Therapeutic areas
- Oncology
- Modalities
- Small molecule
- Industry
- Biotech
02
Drug pipeline
1 assetBeyond the preview
Go deeper on Chaser Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Chaser Therapeutics.